We are live on
!
Find out more
SAM
Sectoral Asset Management Portfolio holdings
AUM
$121M
1-Year Est. Return
73.47%
This Fund
S&P 500
This Quarter
Est. Return
-7.64%
1 Year Est. Return
+73.47%
3 Year Est. Return
+165.77%
5 Year Est. Return
+169.27%
10 Year Est. Return
+1,136.49%
AUM
$563M
AUM Growth
-$101M
(-15%)
Cap. Flow
-$27M
Cap. Flow
% of AUM
-4.8%
Top 10 Holdings %
Top 10 Hldgs %
25.13%
Holding
123
New
15
Increased
30
Reduced
43
Closed
17
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
+$13.2M |
| 2 |
HealthEquity
HQY
|
+$13M |
| 3 |
BioMarin Pharmaceuticals
BMRN
|
+$7.95M |
| 4 |
Tandem Diabetes Care
TNDM
|
+$7.45M |
| 5 |
ITOS
iTeos Therapeutics
ITOS
|
+$5.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ARNA
Arena Pharmaceuticals Inc
ARNA
|
+$21.4M |
| 2 |
Alignment Healthcare
ALHC
|
+$10.3M |
| 3 |
Definitive Healthcare
DH
|
+$7.8M |
| 4 |
TG Therapeutics
TGTX
|
+$7.6M |
| 5 |
NVTA
Invitae Corporation
NVTA
|
+$6.27M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 95.69% |
| 2 | Industrials | 4.31% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
iRhythm Holdings
IRTC
$4.1B
| $4.54M | 0.81% |
+28,800
| New | +$3.7M |
|
52
Danaher
DHR
$139B
| $4.42M | 0.79% |
17,005
-1,917
| -10% | -$480K |
|
53
Arcutis Biotherapeutics
ARQT
$3.25B
| $4.22M | 0.75% |
219,136
-24,600
| -10% | -$416K |
|
|
IMGN
54
DELISTED
Immunogen Inc
IMGN
| $4.18M | 0.74% |
+878,844
| New | +$4.87M |
|
|
JBIO
55
Jade Biosciences
JBIO
$1.16B
| $4.01M | 0.71% |
6,255
-1,824
| -23% | -$708K |
|
56
Treace Medical Concepts
TMCI
$303M
| $3.99M | 0.71% |
211,024
-20,000
| -9% | -$389K |
|
57
Novavax
NVAX
$1.22B
| $3.72M | 0.66% |
50,500
+6,200
| +14% | +$553K |
|
58
Iovance Biotherapeutics
IOVA
$1.93B
| $3.7M | 0.66% |
+222,000
| New | +$3.43M |
|
59
Biogen
BIIB
$29.8B
| $3.62M | 0.64% |
17,202
+120
| +0.7% | +$26.1K |
|
60
DexCom
DXCM
$33B
| $3.58M | 0.64% |
28,000
+7,700
| +38% | +$842K |
|
|
APLS
61
DELISTED
Apellis Pharmaceuticals
APLS
| $3.53M | 0.63% |
+69,500
| New | +$3.07M |
|
|
EXAI
62
DELISTED
Exscientia Plc American Depositary Shares
EXAI
| $3.39M | 0.6% |
235,683
-65,750
| -22% | -$1.12M |
|
63
Elevance Health
ELV
$83B
| $3.39M | 0.6% |
6,900
+1,275
| +23% | +$583K |
|
|
RPTX
64
DELISTED
Repare Therapeutics
RPTX
| $3.39M | 0.6% |
237,785
+31,000
| +15% | +$460K |
|
65
Centene
CNC
$31.5B
| $3.28M | 0.58% |
+39,000
| New | +$3.2M |
|
|
AXNX
66
DELISTED
Axonics, Inc. Common Stock
AXNX
| $3.1M | 0.55% |
+49,500
| New | +$2.67M |
|
|
CNVY
67
DELISTED
Convey Health Solutions Holdings, Inc.
CNVY
| $3.06M | 0.54% |
467,793
-57,180
| -11% | -$377K |
|
68
Maravai LifeSciences
MRVI
$947M
| $3M | 0.53% |
85,000
-25,000
| -23% | -$838K |
|
69
Moderna
MRNA
$21.9B
| $2.96M | 0.53% |
17,205
-850
| -5% | -$143K |
|
70
Molina Healthcare
MOH
$10.2B
| $2.72M | 0.48% |
+8,150
| New | +$2.51M |
|
71
Amgen
AMGN
$204B
| $2.7M | 0.48% |
11,150
-803
| -7% | -$184K |
|
72
Rallybio
RLYB
$84.6M
| $2.69M | 0.48% |
48,134
+10,481
| +28% | +$867K |
|
73
Cytokinetics
CYTK
$10.4B
| $2.58M | 0.46% |
+70,000
| New | +$2.49M |
|
74
908 Devices
MASS
$345M
| $2.56M | 0.46% |
134,872
| – | – |
|
75
Cigna
CI
$74.6B
| $2.55M | 0.45% |
+10,650
| New | +$2.49M |
|
Similar funds
RIP
LFWA
CF
WIM
MW
AFC
TGM
BIS
Sectoral Asset Management's Q1 2022 Portfolio in Review
As of Q1 2022, Sectoral Asset Management held 123 positions worth $563M, down 15% from $664M the previous quarter. Its ten largest holdings account for 25% of the portfolio.
Sectoral Asset Management withdrew a net $27M in Q1 2022, closing 17 positions and reducing 43 holdings. Its most notable exit was Arena Pharmaceuticals Inc, an estimated $21.4M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 95% a quarter earlier, followed by Industrials.
Against the trend, Sectoral Asset Management opened a new position in Biohaven Pharmaceutical Holding Company Ltd. worth $12.6M.
- Sectoral Asset Management's largest Q1 2022 buy was Biohaven Pharmaceutical Holding Company Ltd.: 105,850 shares worth $12.6M.
- Sectoral Asset Management added most to BioMarin Pharmaceuticals in Q1 2022, an estimated $7.95M increase.
- Sectoral Asset Management's biggest Q1 2022 reduction was Amicus Therapeutics, cutting an estimated $5.8M.
- Sectoral Asset Management fully exited Arena Pharmaceuticals Inc in Q1 2022, selling an estimated $21.4M.
- Sectoral Asset Management's ten largest holdings make up 25% of its $563M portfolio in Q1 2022.
- Sectoral Asset Management opened 15 new positions and closed 17 in Q1 2022.
- Sectoral Asset Management's portfolio value fell 15% quarter-over-quarter to $563M.
Based on Sectoral Asset Management's 13F filing for Q1 2022, filed 10 May 2022.